Introduction
============

Breast cancer is the most common cancer in women and about one in eight (12%) will develop invasive breast cancer in their lifetime in the United States. It is estimated that 246,660 new breast cancer cases will be diagnosed and 40,450 will die in 2016 [@B1]. Estrogen receptor α-positive (ER+) and/or progesterone receptor-positive (PR+) --- hormone receptor-positive (HR+) --- breast cancer is consisted of \~65 to 80% of all breast cancers, which is treated with endocrine therapy and/or chemotherapy [@B2], [@B3]. As for HR-negative breast cancer including triple-negative (TNBC; ER-, PR- and human epidermal growth receptor 2-negative \[HER2-\]), cytotoxic chemotherapy is a major element of multi-modality managements [@B4], [@B5]. Chemotherapy is also recommended to patients with node-positive and HER2-positive disease in early stage breast cancer. Radiation therapy is routinely given to patients with invasive breast cancer who received lumpectomy [@B6]. Radiation may be recommended after mastectomy for patients either with a cancer larger than 5 cm or node-positive disease.

The DNA double-strand breaks (DSB) can initiate genomic instability and frequently predispose to cancer development [@B7]. Histone H2AX becomes rapidly phosphorylated at serine 139 residues from the N terminus, referred to as γH2AX, in the DSB sites and at the break spots in the chromosomes. Thus, it is widely used as a surrogate marker of DSBs. Importantly, γH2AX can be induced upon exposure to ionizing irradiation and some chemotherapy agents [@B8], [@B9], and has been shown to play a role in DNA damage response signaling and initiate the repair of DSBs [@B10]. In addition, constitutive expression of γH2AX was associated with short telomere and BRACness status [@B11]. DSBs (γH2AX) repair under hypoxia condition was compromised at times and resulted in the persistent presence of γH2AX and chromosomal instability [@B12].

Despite extensive experimental research, only a few studies evaluated the constitutive γH2AX expression in human tumor specimens [@B13], [@B14]. It remains unclear whether the constitutive expression of γH2AX at diagnosis is associated with clinical outcomes that is potentially impacted by standard therapy. Based on the characteristic induction of γH2AX by cancer therapeutics and irradiation, we hypothesized that γH2AX status may influence clinical outcome imposed by specific treatment(s) in cancer. Herein, we assessed long-term clinical outcome of patients with stage I, II and III breast cancer with and without γH2AX expression in their tumors after undergoing uniform treatments and within no treatment besides surgery.

Patients and methods
====================

Patients, specimens and data collection
---------------------------------------

Patients were diagnosed with stage I, II and III breast cancer at hospitals participating in the accreditation program of the Commission on Cancer of the American College of Surgeons. Breast cancer specimens were collected in hospitals in the geographic areas that were covered by the four institutions represented by the Cooperative Breast Cancer Tissue Resource (CBCTR): Fox Chase Cancer Center, Kaiser Permanente Northwest Region, Jackson Memorial Hospital-University of Miami, and the Washington University. The tissues were generally representative of breast cancer diagnosed in the community hospital setting. Institutional pathologists reviewed slides for confirmation of tumor presence and histology from the blocks using a common protocol and coding scheme. The dataset established by the breast cancer registries of these hospitals included clinical and pathological variables, types of treatment received, and long-term clinical follow-up [@B15]. The coded data were maintained centrally in a single database.

A breast cancer prognostic tissue microarray (TMA) was designed and developed by the National Cancer Institute Cancer Diagnosis Program using 1169 tumor specimens from the 1169 CBCTR patients with invasive breast cancer diagnosed from 1985 to 1997. ER, PR or HER2 status was centrally assayed and reviewed by the CBCTR pathologists. According to the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) guidelines, ER and PR were considered positive if \>1% of tumor cells stained. For HER2 scoring, cases were defined as negative if immunohistochemistry (IHC) 0, 1+, and 2+ when fluorescence in situ hybridization (FISH) non-amplified or no IHC but FISH non-amplified. Tumor samples were classified as positive if IHC 3+ or IHC 2+/1+ with FISH amplified or IHC not available and FISH amplified. Approval of the study on the de-identified human tissues was obtained from the Office of Human Research Protections, National Institutes of Health, Bethesda, Maryland. The biomarker study was carried out according to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria [@B16].

γH2AX Immunohistochemistry and analysis
---------------------------------------

γH2AX expression on formalin-fixed paraffin-embedded primary tumors in two sets of prognostic breast cancer TMA with 1169 cases was examined by immunohistochemistry [@B8], [@B17]. In brief, epitope retrieval was performed in antigen retrieval buffer pH6.0 (DAKO, Carpinteria, CA) and heated in a pressure cooker at 121^o^C for 5 minutes. The sections were incubated with a mouse monoclonal antibody to γH2AX (clone JBW301, Millipore, Temecula, CA) in 1:300 dilution at room temperature. The antibody specificity was validated by Western blot (supplementary Figure [1](#SM1){ref-type="supplementary-material"}). Binding of the antibody to the antigenic sites was amplified using Vectastain Elite avidin-biotin-peroxidase complex kits (Vector Laboratories, Burlingame, CA). The immuno-reaction sites were revealed by color development using 3, 3\'-diaminobenzidine (DAB) for 5 minutes (Sigma, St. Louis, MO), and followed by counterstaining with hematoxylin. The topotecan-treated colorectal cancer HCT116 and breast cancer MCF-7 cells, with augmented γH2AX signal *versus* untreated, were used as positive controls for gamma-H2AX staining. A breast cancer specimen that expresses endogenous γH2AX was also utilized as the positive control.

γH2AX staining in the malignant nuclei in one representative set of the TMAs was quantitatively scored with the assistance of an Automated Cellular Imaging System (ACIS III, DAKO) blinded to all clinical information at the time of scoring. Missing tissue cores and the cores with \< 5% of invasive tumor cells present were excluded for analysis. The intensity and percentage of stained tumor cells on each sample was generated using a free-scoring tool assisted by the digital imaging instrument. Staining index was determined by percentage multiplied by intensity of staining divided by 100 as previously described [@B18]. Staining index of ≥ 2 (range, 0 to 40) was chosen as the cutoff for γH2AX positivity. It reflects γH2AX expression with a visual intensity of 1+, 2+ and 3+ in the stained tumor cells including diffuse and heterogeneous expression patterns. p53 staining was described previously and ≥10% of malignant nuclei staining was defined as positive [@B18].

Statistical analysis
--------------------

Chi-squared test of association was used to compare categorical variables between γH2AX-positive and γH2AX-negative tumors. Length of follow-up for overall survival (OS) was defined as number of months from date of diagnosis to date of death due to any cause, or to date last known alive. The length of recurrence-free survival (RFS) was calculated as the number of months from date of diagnosis to the date of first occurrence of ipsilateral invasive breast tumor recurrence, local/regional recurrence (chest wall, ipsilateral axillary and internal mammary nodes), distant recurrence, or death due to any cause. Time to event outcomes among 573 patients undergoing uniform therapy including OS and RFS used the Kaplan-Meier method and the log-rank test for association. These included chemotherapy alone group with 118 patients, 78 patients with radiation therapy alone, and 133 patients with endocrine therapy alone, as well as 244 patients with no treatment. The 253 patients who received combination treatment either radiation/chemotherapy, endocrine/chemotherapy, radiation/endocrine therapy or radiation/chemotherapy/endocrine therapy were excluded for clinical outcome analyses. Cox\'s proportional hazards method was used for multivariable models. A P value less than 0.05 was considered statistically significant. All statistical analysis was performed in R.

Results
=======

Constitutive γH2AX expression in breast cancer
----------------------------------------------

Of 1169 cases, 826 patients had γH2AX staining data. γH2AX was constitutively expressed in 24% (200/826) of the patients with stage I, II and III breast cancer. There was a dynamic range of γH2AX staining from negative to those from weak to moderate and strong (Figure [1](#F1){ref-type="fig"}). Both heterogeneous (Figure [1](#F1){ref-type="fig"}B1, 1B2, and 1C1) and diffuse staining patterns (Figure [1](#F1){ref-type="fig"}C2, 1D1 and 1D2) were observed in γH2AX-positive breast tumors. Importantly, we detected three forms of nuclear γH2AX distribution. These were pan-nuclear γH2AX foci (Figure [1](#F1){ref-type="fig"}B1, 1B2, 1C1 and 1D1), mixed pan-nuclear and nuclear-ring type of γH2AX (Figure [1](#F1){ref-type="fig"}C2), and predominant nuclear-ring pattern (Figure [1](#F1){ref-type="fig"}D2) in the breast tumors.

Association of γH2AX with patient and clinicopathologic variables
-----------------------------------------------------------------

Patients had a median age of 60 years at diagnosis with a range of 25 to a maximum of 96 years. Table [1](#T1){ref-type="table"} summarizes the clinicopathologic and molecular factors distinguished by γH2AX status, in which γH2AX-positive tumors had significantly higher tumor grade (P\<0.0001). By analysis of the three components of tumor grade according to the Bloom-Richardson grading system [@B19], γH2AX was significantly associated with mitotic index (P\<0.0001), followed by nuclear pleomorphism (P=0.004), and not significantly with tubule formation (P=0.08). Additionally, γH2AX-positive status was associated with more HR-negative or triple-negative and p53-positive staining as well as HER2 positivity (P\<0.0001). It has a trend towards association with infiltrating ductal histology than lobular carcinoma or with stage II/III disease. γH2AX expression was not significantly associated with age at diagnosis, tumor size and lymph node involvement. Node-positive breast cancer was consisted of \~44% of the study cohort, in which 46% was γH2AX-positive tumors.

Overall survival by γH2AX status in uniform treatment groups
------------------------------------------------------------

The median follow-up for OS in 826 patients with γH2AX data was 176 months (\~15 years), ranged from 13 (1.1 years) to 282 (23.5 years) months. Pertaining to the role of γH2AX on DNA damage response and its characteristic induction by cytotoxic chemotherapy and irradiation, we postulated that clinical outcome may be more impacted by specific treatment in patients with γH2AX-positive tumors than those with γH2AX-negative tumors. Indeed, a statistically significant heterogeneity in OS was detected in γH2AX-positive patients among uniform treatment groups including chemotherapy, radiation and endocrine therapy, as well as no treatment, being poorest by chemotherapy (n=129; overall log-rank test, Chi-square=14.7, p value of 0.0021, testing if at least one group is different). By contrast, the heterogeneity for OS in γH2AX-negative cases was not statistically significant (n=444, P=0.187).

In the chemotherapy group, median OS was 63 months (95% confidence interval \[CI\], 29 - 83) in patients with γH2AX-positive tumors, compared with 170 months (95% CI 94 - 235) in those with γH2AX-negative tumors (P=0.0016; Figure [2](#F2){ref-type="fig"}A). The Kaplan-Meier curves between positive and negative patients were separated at the beginning of follow-up and gradually widened up to \~20 years. By multivariable Cox regression modeling analysis, γH2AX status remained to be poor prognostic; and was associated with an increased risk of death by an adjusted factor of 2.12 during follow-up in the chemotherapy group (P=0.0091, Table [2](#T2){ref-type="table"}). Noticeably, patient and disease characteristics in the chemotherapy group were similar to the whole study cohort between γH2AX-positive and γH2AX-negative tumors, with proportional increase of patients with poor prognostic features such as node-positive, HER2-positive or ER-negative (Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

γH2AX scores were not significantly associated with long-term OS in patients treated with radiation therapy alone (n=78, P=0.153, Figure [2](#F2){ref-type="fig"}B) and endocrine therapy alone (n=133, P=0.938, Figure [2](#F2){ref-type="fig"}C), respectively. In addition, γH2AX did not predict OS within patients who did not receive treatment (n=244, P=0.877, Figure [2](#F2){ref-type="fig"}D). During the follow-up period, it appears that γH2AX expression had a trend towards association with an inferior RFS than no expression in the chemotherapy group (n=111, P=0.11).

Discussion
==========

In this study, we demonstrated that γH2AX is expressed in a significant fraction of human primary breast tumors, with three main forms of nuclear γH2AX distribution: pan-nuclear γH2AX foci, mixed pan-nuclear and nuclear-ring type, and predominant nuclear-ring pattern [@B20]. It was significantly associated with poor tumor differentiation that is more influenced by mitotic index and nuclear pleomorphism, is likely reflective of the genomic instability in these breast tumors. It is implicated in the aggressive features for more frequent association with HER2 expression and hormone receptor negative or triple-negative status, as well as positive p53 staining, largely consistent with the findings of Nagelkerke et al in node-negative breast cancer [@B13]. The data suggest γH2AX as a potential therapeutic target in breast cancer and likely in other cancer types [@B13], [@B14]. A substantial reduction versus minor decrease of γH2AX under chronic oxidative stress was shown to be associated with better response to neoadjuvant therapy and survival in patients with triple-negative breast cancer [@B21]. Thus, specific targeting γH2AX holds promise for cancer treatment and its druggability warrants preclinical development, and clinical evaluation.

γH2AX is the first molecular marker identified that can reveal the survival heterogeneity in γH2AX-positive but not γH2AX-negative breast cancer patients across the uniform treatment groups. By both univariate and multivariable analyses, expression of γH2AX was significantly associated with inferior survival in the chemotherapy group (likely cyclophosphamide, methotrexate and 5- fluorouracil, CMF, regimen during the follow-up period). The chemotherapy agents are widely used in the treatment of many cancer types such as gastrointestinal cancers including colorectal/pancreatic/stomach, lung cancer, leukemia/lymphoma, and ovarian carcinoma besides breast cancer. Notably, the impact of chemotherapy on survival occurred early and worsened over a long-term of clinical follow-up. By contrast, OS rates were not significantly different between γH2AX-positive and γH2AX-negative patients who did not receive therapy. Therefore, we confirmed our hypothesis that constitutive γH2AX-positive status is associated with long-term poor clinical outcome that is impacted by specific treatment (chemotherapy) in breast cancer.

Taken together, these data suggest that level of DNA damage caused by systemic chemotherapy was less effective to eliminate the γH2AX-positive residue or resistant tumors, relative to γH2AX-negatvie tumors. In fact, phosphorylation of H2AX facilitates the assembly of DNA repair proteins at the sites containing DNA double strand breaks and damaged chromatin [@B22], [@B23]. The prolonged activation in DNA damage response did sometimes result in the survival of malignant cells [@B24]. Currently, systemic chemotherapy is one of the multi-modality managements for early stage breast cancer, particularly for those with poor clinicopathologic features and prognosis such as node-positive and HER2-positive as well as HR-negative/triple-negative breast cancer [@B5]. Chemotherapy is also one of the major treatments for locally recurrent and metastatic breast cancer [@B25], [@B26]. Recently, Lobbezoo and colleagues reported that high percentage of HR-positive metastatic breast cancer patients received initial palliative chemotherapy, which was associated with worse outcome for OS and progression-free survival than endocrine therapy [@B27]. In brief, chemotherapy might not be effective for patients with γH2AX-positive tumors, both early (I and II) stage, locally advanced stage (III), and perhaps metastatic breast cancer either HR-negative or HR-positive.

The insignificant association of γH2AX and worsening long-term outcome in patients with γH2AX-positive tumors by radiation therapy alone could be explained as the following: DNA damage delivered by local-regional radiation was relatively adequate to eliminate γH2AX-positive residue tumors as well as γH2AX-negative tumors alike. Furthermore, it is not surprising that γH2AX scores did not significantly predict long term clinical outcome after endocrine therapy given the mechanisms of action of anti-hormonal agents [@B28].

In this large cohort study, γH2AX, a DNA damage response marker, is expressed in a significant percentage of patients with stage I, II and III breast cancer besides other DNA damage response proteins such as poly(adenosine diphosphate-ribose) polymerase (PARP) 1 [@B29], [@B30]. We found substantial survival heterogeneity in γH2AX-positive patients among uniform treatment groups, in contrast to γH2AX-negative patients. Through long-term clinical follow-up, γH2AX is significantly associated with poor OS in patients who received chemotherapy alone by both univariate and multivariable analyses. Thus, γH2AX is a poor prognostic factor in patients who received systemic chemotherapy. Such data can be subsequently utilized in the design of clinical trials to test γH2AX and the effects of treatment in breast cancer as well as in many other cancer types. The findings may ultimately lead to the improvement of breast cancer patient care, broadly cancer particularly those with poor prognosis.

Supplementary Material {#SM0}
======================
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Supplementary figure 1 and table 1.

###### 

Click here for additional data file.
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![Constitutive expression of γH2AX in primary breast tumors. The representative views of γH2AX staining from top to bottom are negative (**A1** and **A2**), weak (**B1** and **B2**), moderate (**C1** and **C2**), and strong (**D1** and **D2**). Note a case of predominant nuclear γH2AX ring staining pattern (**D2**). Original magnification, x600; scale bar, 50 µm.](thnov07p0945g001){#F1}
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###### 

γH2AX status in relation to patient and clinicopathologic variables.

  Variable                 Total 826 patients No. (%)   γH2AX-positive (200 patients) No. (%)   γH2AX-negative (626 patients) No. (%)   P value
  ------------------------ ---------------------------- --------------------------------------- --------------------------------------- ----------
  Age at Diagnosis                                                                                                                      0.360
  \<50 yr                  217 (26.3)                   58 (29.0)                               159 (25.4)                              
  ≥50 yr                   609 (73.7)                   142 (71.0)                              467 (74.6)                              
  T stage†                                                                                                                              0.143
  T0                       0                            0                                       0                                       
  T1                       468 (56.7)                   103 (51.5)                              365 (58.3)                              
  T2                       222 (26.9)                   54 (27.0)                               168 (26.8)                              
  T3                       88 (10.6)                    27 (13.5)                               61 (9.7)                                
  T4                       48 (5.8)                     16 (8.0)                                32 (5.1)                                
  N stage                                                                                                                               0.331
  N0                       460 (55.8)                   108 (54.0)                              352 (40.6)                              
  N1                       318 (38.5)                   79 (39.5)                               239 (38.2)                              
  N2                       46 (5.6)                     12 (6.0)                                34 (5.4)                                
  N3                       1 (0.1)                      1 (0.1)                                 0 (0.0)                                 
  Tumor size                                                                                                                            0.148
  \<2 cm                   370 (44.8)                   82 (41.0)                               288 (46.0)                              
  2-5 cm                   350 (42.4)                   85 (42.5)                               265 (42.3)                              
  \>5 cm                   105 (12.7)                   33 (16.5)                               72 (11.5)                               
  Histology                                                                                                                             0.052
  Ductal                   760 (92.0)                   191 (95.5)                              569 (90.9)                              
  Lobular                  66 (8.0)                     9 (4.5)                                 57 (9.1)                                
  Tumor grade                                                                                                                           \<0.0001
  I                        184 (22.3)                   30 (15.0)                               154 (24.6)                              
  II                       379 (45.9)                   78 (39.0)                               301 (48.0)                              
  III                      263 (31.8)                   92 (46.0)                               171 (27.3)                              
  Stage                                                                                                                                 0.073
  I                        354 (42.9)                   75 (37.5)                               279 (44.6)                              
  II                       315 (38.1)                   77 (38.5)                               238 (38.0)                              
  III                      157 (19.0)                   48 (24.0)                               109 (17.4)                              
  Estrogen receptor                                                                                                                     \<0.0001
  Negative                 221 (26.9)                   80 (40.2)                               141 (22.7)                              
  Positive                 600 (73.1)                   119 (59.8)                              481 (77.3)                              
  Hormone receptor                                                                                                                      \<0.0001
  Negative                 183 (22.3)                   72 (36.2)                               111 (17.8)                              
  Positive                 638 (77.7)                   127 (63.8)                              511 (82.2)                              
  HER2 status                                                                                                                           0.001
  Negative                 691 (83.9)                   152 (76.4)                              539 (86.2)                              
  Positive                 133 (16.1)                   47 (23.6)                               86 (13.8)                               
  p53                                                                                                                                   \<0.0001
  Negative                 504 (61.0)                   90 (45.0)                               414 (66.1)                              
  Positive                 155 (18.8)                   62 (31.0)                               93 (14.9)                               
  Unknown                  167 (20.2)                   48 (24.0)                               119 (19.0)                              
  Triple negative status   125                          42 (33.6)                               83 (66.4)                               0.011

HER2, human epidermal growth receptor 2; No, number.

###### 

Adjusted hazard ratio in OS by multivariate Cox regression modeling in chemotherapy group (No.=118).

  Variable            Adjusted HR (95% CI)   P value
  ------------------- ---------------------- ---------
  γH2AX-positive      2.12 (1.21 - 3.74)     0.009
  Age at diagnosis    1.02 (1.21 - 3.74)     0.054
  Tumor size          1.09 (0.99 - 1.19)     0.072
  Estrogen receptor   0.71 (0.42 - 1.19)     0.196
  Lymph node status                          
  N0                  1.00                   \-
  N1                  2.03 (1.07 - 3.85)     0.030
  N2                  3.74 (1.53 - 9.14)     0.004
  N3                  7.330 (0.81 - 66.7)    0.076

CI, confidence interval; HR, hazard ratio; No, number; OS, overall survival.
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